In 10-15% of cancers, homozygous deletion of MTAP results in accumulation of MTA, which competes with SAM for the PRMT5 cofactor binding pocket, inhibiting methyltransferase activity (Fig. 1B)17. This evidence concerns the gene MTAP and cancer.